VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Probable or definite diagnosis of autoimmune       │ Probable or definite diagnosis of autoimmune       │     100 │
│ hepatitis according to the International           │ hepatitis according to the International           │         │
│ Autoimmune Hepatitis Study Group criteria          │ Autoimmune Hepatitis Study Group criteria          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ First presentation of AIH requiring treatment      │ First presentation of AIH requiring treatment      │     100 │
│ according to the current EASL guidelines           │ according to the current EASL guidelines           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must provide informed consent and agree to comply  │ Must provide informed consent and agree to comply  │     100 │
│ with the trial protocol                            │ with the trial protocol                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Overlap syndrome with Primary Sclerosing           │ Overlap syndrome with Primary Sclerosing           │     100 │
│ Cholangitis (PSC) or Primary Biliary Cholangitis   │ Cholangitis (PSC) or Primary Biliary Cholangitis   │         │
│ (PBC) (Paris criteria, strong positive Anti-       │ (PBC) (Paris criteria, strong positive Anti-       │         │
│ Mitochondrial Antibodies (AMA), past liver biopsy  │ Mitochondrial Antibodies (AMA), past liver biopsy  │         │
│ or cholangiographic findings compatible with PBC   │ or cholangiographic findings compatible with PBC   │         │
│ or PSC)                                            │ or PSC)                                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presentation with acute liver failure, defined as  │ Presentation with acute liver failure, defined as  │     100 │
│ presence of hepatic encephalopathy and             │ presence of hepatic encephalopathy and             │         │
│ coagulopathy (INR \> 1.5)                          │ coagulopathy (INR > 1.5)                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current treatment with prednisone/prednisolone     │ Current treatment with prednisone/prednisolone     │     100 │
│ and/or immunosuppressive medication for an         │ and/or immunosuppressive medication for an         │         │
│ indication other than autoimmune hepatitis         │ indication other than autoimmune hepatitis         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current systemic infection                         │ Current systemic infection                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Other clinically significant medical conditions    │ Other clinically significant medical conditions    │     100 │
│ that could interfere with the trial                │ that could interfere with the trial                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ If female of childbearing potential: known         │ If female of childbearing potential: known         │     100 │
│ pregnancy, or unwilling to practice                │ pregnancy, or unwilling to practice                │         │
│ anticontraceptive measures                         │ anticontraceptive measures                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of noncompliance with medical regimens, or │ History of noncompliance with medical regimens, or │     100 │
│ patients who are considered to be potentially      │ patients who are considered to be potentially      │         │
│ unreliable or unable to participate                │ unreliable or unable to participate                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Mental instability or incompetence, such that the  │ Mental instability or incompetence, such that the  │     100 │
│ validity of informed consent or compliance with    │ validity of informed consent or compliance with    │         │
│ the trial is uncertain                             │ the trial is uncertain                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥ 18 years                                     │ Age = 18 years                                     │      93 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria   │   Score │
╞═══════════════════════════════════╪═════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Age = 18 years  │      47 │
╘═══════════════════════════════════╧═════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 99
Average Levenshtein Ratio of individual lines: 95.38461538461539
OverAll Ratio: 97.1923076923077
